[{"orgOrder":0,"company":"Encellin","sponsor":"Khosla Ventures","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Financing","leadProduct":"ENC-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Encellin","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Encellin \/ Khosla Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Encellin \/ Khosla Ventures"}]

Find Clinical Drug Pipeline Developments & Deals by Encellin

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The financing will advance a Phase 1 clinical trial evaluating subcutaneous transplantation of primary islets within Encellin’s encapsulated cell replacement therapy, ENC-201, in Type 1 Diabetes (T1D).

                          Product Name : ENC-201

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          December 13, 2023

                          Lead Product(s) : ENC-201

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Khosla Ventures

                          Deal Size : $9.9 million

                          Deal Type : Financing

                          blank